Webinar organized by VIVAN Therapeutics on May 2nd at 4 pm (BST) to discuss opportunities around multi-target drug discovery in oncology, in particular around KRAS resistance and Vivan Therapeutics's humanised Drosophila KRAS specific variant models for Biopharma discovery & development.

During this webinar, VIVAN will introduce a suite of KRAS variant models available to biopharma for competitive profiling, drug discovery and development. VIVAN will also demonstrate a use case for their models and discuss a groundbreaking partnership between Vivan and Dr. Albert Antolin (ICR/IDIBELL) for the development of multi target therapeutics.

The webinar is available freely via this link (starts from minute 4:30):


(Passcode: 9bsv3A$n)


It has been estimated that the whole medical knowledge doubles approximately every year and by the end of 2021 it will happen every 2 months. Nowadays the health system is one of the major data generators, which, in combination with the enhanced computing power is paving the way for a pervasive use of artificial intelligence (AI) to manage, interpret and generate new knowledge from biomedical data at an unprecedented scale. AI is opening new, yet unexplored avenues for generating biological and medical knowledge linking both, genetic variation and environment, to phenotypes by analyzing clinical and genomic Big Data together. However, most of these data are affected by data protection rules and reside within restricted access hospital environments, which has fostered the emergence of some imaginative recent proposals such as federate AI learners or the generation of highly realistic simulated patients based on deep learning networks. All these novelties brought about by AI are not exempt of limitations, including privacy and security issues, bias, and lack of interpretability, and will be discussed in this workshop along with the future directions of AI in biomedicine.


The workshop will be held in Baeza, at the “Sede Antonio Machado”, a XVII century building turned into a Conference Centre of the Universidad Internacional de Andalucía (UNIA). This Seat includes a residence, where participants will be accommodated. Baeza is a World Historic Heritage town, renowned for its Renaissance and Gothic buildings.


The ECBS 2021 brings together scientists from Europe and overseas to present and discuss their latest achievements in cutting edge chemical sciences at the interface with biology and medicine, ranging from new therapeutic approaches to resistant pathogens and viral infections (special session on COVID19 research), to targeting of proteasome and protein aggregation, natural products, artificial intelligence in drug discovery, nanostructured biomaterials, synthetic biology, glycochemistry and biology, chemistry of life origin.

I was selected to present my work in a special section on Artificial intelligence & computational drug design and my talk was entitled  "From probe to drug: polypharmacology across drug discovery". Website

Target 2035 is an open science global movement consisting of international scientists and researchers, focusing on the creation of chemical and biological tools to study human proteins and inform drug discovery. I am part of this initiative and I was invited to present at one of their monthly webinars.

Together with Prof. Paul Workman, we presented the updated Chemical Probes Portal, a free, online, expert-curated resource to help researchers identify the best chemical probes for their targets of interest. Recording available.

The 6th European Chemical Biology Symposium and the meeting of the EuChemS Division “Chemistry in Life Sciences” (LS-EuChemS) and it is jointly organized by EuChemS and EU-OPENSCREEN. This meeting builds on the success of 4th ICBS/ECBS joint meeting in Berlin (2015) and 5th ECBS in Budapest (2017).

I was selected to present my work in a special section on the EU OPENSCREEN project and my talk was  "Probe Miner v2: updated objective, data-driven assessment of chemical probes". Website

Joomla templates by a4joomla